+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID05823311

Study of Lenvatinib and Tislelizumab with Gemcitabine and Cisplatin to Treat Advanced Cholangiocarcinoma Randomized, Double-Blind Phase 3 Trial Evaluating Safety and Effectiveness

Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-02-10

80

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Advanced cholangiocarcinoma CCA is a group of aggressive cancers that start in the bile duct cells and are often diagnosed late, making surgery impossible for many patients. With new chemotherapy, targeted therapies, and immunotherapy options emerging, this research evaluates the safety and effectiveness of combining Lenvatinib, Tislelizumab, and Gemcitabine plus Cisplatin GPLET for treating advanced CCA. The study is a Phase 3 randomized, double-blind trial sponsored by the Second Affiliated Hospital, School of Medicine, Zhejiang University. Participants are assigned to one of two groups. One group receives intravenous gemcitabine and cisplatin plus tislelizumab and oral lenvatinib, while the other group gets intravenous gemcitabine and cisplatin with placebo and oral placebo tablets. Treatments are given in 21-day cycles, with four cycles making up the primary treatment period. This design allows comparison between the combined therapy and standard chemotherapy with placebo. During the study, participants will be monitored for tumor response, with the main outcome being the objective remission rate after four treatment cycles. Additional measures include progression-free survival and overall survival over up to 60 months. Safety and organ function will be checked regularly, and participants will be followed long term to assess treatment impact and side effects. Total participation duration varies with follow-up assessments continuing after treatment completion.

CONDITIONS

Brief Title

Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Research Team

W

Weilin Wang, doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here